# Innorna Nominated for 2026 Prix Galien USA Best Startup Award

- Link: https://www.thailand-business-news.com/pr-news/innorna-nominated-for-2026-prix-galien-usa-best-startup-award
- Published: 2026-08-13T21:00:00+07:00
- Author: PR Newswire

|   |

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/—
Innorna, a clinical-stage biotech company advancing RNA medicines, today announced
that it has been nominated for the _2026 Prix Galien USA Best Startup Award._

Innorna was shortlisted in the Best Startup category, reflecting the innovation 
in its mRNA-LNP platform and a clinical pipeline that has advanced beyond vaccines
into therapeutics. The company’s lead program, IN026, is a novel mRNA therapy for
refractory gout, designed to reduce uric acid. It received FDA IND clearance in 
March 2026, extending mRNA-based protein replacement into common chronic disease.

Widely regarded as the equivalent of the "Nobel Prize of the biopharmaceutical industry,"
the Prix Galien honors extraordinary achievements in medical innovation that improve
human health. Winners are selected by committees of leading biomedical scientists,
industry executives, and Nobel Laureates from around the world.

"We are honored to be named a Prix Galien USA Best Startup nominee," said Dr. Linxian
Li, Founder and CEO of Innorna. "The nomination reflects the progress our team has
made in advancing our clinical pipeline, built on years of dedicated platform engineering.
It is also a reminder of why we do this work: _to develop RNA medicines that can
offer better options to patients and improve lives worldwide."_ 

The winners of the 2026 Prix Galien USA Awards will be announced at the Awards Ceremony
on October 29, 2026, at the American Museum of Natural History in New York City.

**About Innorna**

Innorna is a clinical-stage biotech advancing RNA medicines by accelerating a virtuous
cycle of platform and pipeline innovation – improving lives worldwide. Backed by
a substantial and growing intellectual property portfolio, the company has built
a proprietary, differentiated RNA delivery and engineering platform spanning a rationally
designed library of over 6,000 chemically diverse ionizable lipids, targeted LNP
delivery systems, and mRNA technologies. Its vertically integrated capabilities,
from discovery through cGMP manufacturing, enable deep technical expertise, accelerated
development, and strong capital efficiency. Innorna is advancing a robust mRNA pipeline
across chronic disease therapeutics, _in vivo_ immunotherapies, and vaccines. Innorna
has raised $150 million to date.  

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Innorna Nominated for 2026 Prix Galien USA Best Startup Award ](http://www.prnasia.com/story/archive/5025797_AE25797_0?rand=184833)